Publications by authors named "Hakan Kalyon"
Article Synopsis
- Glofitamab is a bi-specific antibody used to treat relapsed or refractory B-cell lymphoma, showing potential in a phase II trial, but real-world data is limited.
- A retrospective study in Turkey analyzed 43 DLBCL patients receiving glofitamab, revealing median overall survival of 8.8 months and a 1-year progression-free survival rate of 83%.
- While the treatment had promising effectiveness, toxicity was a significant concern, with deaths linked to disease progression and treatment-related side effects like cytokine release syndrome.
Bortezomib is widely used in the treatment of Multiple Myeloma. While the most common side effects are neurological and gastrointestinal related complications, severe pulmonary problems are rarely described. The present case is a 72-year old male with multiple myeloma, who received Lenalidomide, Bortezomib, and Dexamethasone (RVD) combination regimen.
View Article and Find Full Text PDF